BioCryst [BCRX] vs Haleon Plc - ADR [HLN] Detailed Stock Comparison
BioCryst
NASDAQ
Loading...
Haleon Plc - ADR
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: BioCryst wins in 11 metrics, Haleon Plc - ADR wins in 8 metrics, with 0 ties. BioCryst appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | BioCryst | Haleon Plc - ADR | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -19.47 | 21.51 | BioCryst |
| Price-to-Book Ratio | -4.16 | 5.46 | BioCryst |
| Debt-to-Equity Ratio | -1.75 | 53.41 | BioCryst |
| PEG Ratio | 0.15 | 23.05 | BioCryst |
| EV/EBITDA | 38.22 | 36.15 | Haleon Plc - ADR |
| Profit Margin (TTM) | -6.41% | 13.81% | Haleon Plc - ADR |
| Operating Margin (TTM) | 18.23% | 22.21% | Haleon Plc - ADR |
| EBITDA Margin (TTM) | 18.23% | 22.21% | Haleon Plc - ADR |
| Return on Equity | 18.68% | 9.38% | BioCryst |
| Return on Assets (TTM) | 7.46% | 4.61% | BioCryst |
| Free Cash Flow (TTM) | $-53.14M | $2.68B | Haleon Plc - ADR |
| Dividend Yield | N/A | 1.63% | N/A |
| 1-Year Return | 5.68% | -0.81% | BioCryst |
| Price-to-Sales Ratio (TTM) | 3.15 | 3.94 | BioCryst |
| Enterprise Value | $2.24B | $128.54B | Haleon Plc - ADR |
| EV/Revenue Ratio | 4.01 | 8.62 | BioCryst |
| Gross Profit Margin (TTM) | 98.29% | 55.38% | BioCryst |
| Revenue per Share (TTM) | $3 | $2 | BioCryst |
| Earnings per Share (Diluted) | $-0.18 | $0.45 | Haleon Plc - ADR |
| Beta (Stock Volatility) | 1.10 | 0.24 | Haleon Plc - ADR |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
BioCryst vs Haleon Plc - ADR Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| BioCryst | 2.15% | 2.27% | -1.04% | -17.61% | 3.26% | 9.32% |
| Haleon Plc - ADR | 0.10% | 1.76% | 1.76% | -11.21% | -3.25% | 4.03% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| BioCryst | 5.68% | -39.97% | 115.62% | -25.04% | 77.59% | -0.58% |
| Haleon Plc - ADR | -0.81% | 57.62% | 32.52% | 32.52% | 32.52% | 32.52% |
Performance & Financial Health Analysis: BioCryst vs Haleon Plc - ADR
| Metric | BCRX | HLN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.76B | $43.42B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 3,375,290 | 8,652,980 |
| 90 Day Avg. Volume | 3,382,800 | 10,980,153 |
| Last Close | $8.56 | $9.82 |
| 52 Week Range | $6.02 - $11.31 | $8.86 - $11.42 |
| % from 52W High | -24.31% | -14.01% |
| All-Time High | $37.25 (Mar 06, 2000) | $11.42 (Jun 02, 2025) |
| % from All-Time High | -77.02% | -14.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.49% | -0.01% |
| Quarterly Earnings Growth | 0.49% | 0.33% |
| Financial Health | ||
| Profit Margin (TTM) | -0.06% | 0.14% |
| Operating Margin (TTM) | 0.18% | 0.22% |
| Return on Equity (TTM) | 0.19% | 0.09% |
| Debt to Equity (MRQ) | -1.75 | 53.41 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $-2.01 | $1.77 |
| Cash per Share (MRQ) | $1.24 | $0.08 |
| Operating Cash Flow (TTM) | $16.82M | $3.37B |
| Levered Free Cash Flow (TTM) | $53.98M | $2.60B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.63% |
| Last 12-Month Dividend | N/A | $0.17 |
Valuation & Enterprise Metrics Analysis: BioCryst vs Haleon Plc - ADR
| Metric | BCRX | HLN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -19.47 | 21.51 |
| Forward P/E | -209.25 | 23.05 |
| PEG Ratio | 0.15 | 23.05 |
| Price to Sales (TTM) | 3.15 | 3.94 |
| Price to Book (MRQ) | -4.16 | 5.46 |
| Market Capitalization | ||
| Market Capitalization | $1.76B | $43.42B |
| Enterprise Value | $2.24B | $128.54B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.01 | 8.62 |
| Enterprise to EBITDA | 38.22 | 36.15 |
| Risk & Other Metrics | ||
| Beta | 1.10 | 0.24 |
| Book Value per Share (MRQ) | $-2.01 | $1.77 |
Financial Statements Comparison: BioCryst vs Haleon Plc - ADR
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BCRX | HLN |
|---|---|---|
| Revenue/Sales | $145.53M | $3.73B |
| Cost of Goods Sold | $4.57M | $1.66B |
| Gross Profit | $140.97M | $2.07B |
| Research & Development | $37.27M | $105.46M |
| Operating Income (EBIT) | $21.23M | $473.22M |
| EBITDA | $24.58M | $489.44M |
| Pre-Tax Income | $758,000 | $389.39M |
| Income Tax | $726,000 | $89.24M |
| Net Income (Profit) | $32,000 | $300.16M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BCRX | HLN |
|---|---|---|
| Cash & Equivalents | $105.19M | $2.97B |
| Total Current Assets | $409.98M | $7.73B |
| Total Current Liabilities | $139.86M | $7.86B |
| Long-Term Debt | $792.12M | $11.65B |
| Total Shareholders Equity | $-451.93M | $21.94B |
| Retained Earnings | $-1.77B | $36.87B |
| Property, Plant & Equipment | $19.58M | $0 |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BCRX | HLN |
|---|---|---|
| Operating Cash Flow | $21.14M | N/A |
| Capital Expenditures | $-143,000 | N/A |
| Free Cash Flow | $-27.66M | N/A |
| Debt Repayment | $-516,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BCRX | HLN |
|---|---|---|
| Shares Short | 25.88M | 17.45M |
| Short Ratio | 8.05 | 1.39 |
| Short % of Float | 0.12% | 0.00% |
| Average Daily Volume (10 Day) | 3,375,290 | 8,652,980 |
| Average Daily Volume (90 Day) | 3,382,800 | 10,980,153 |
| Shares Outstanding | 208.54M | 12.35B |
| Float Shares | 207.69M | 8.95B |
| % Held by Insiders | 0.01% | 0.00% |
| % Held by Institutions | 0.95% | 0.13% |
Dividend Analysis & Yield Comparison: BioCryst vs Haleon Plc - ADR
| Metric | BCRX | HLN |
|---|---|---|
| Last 12-Month Dividend | N/A | $0.17 |
| Last 12-Month Dividend Yield | N/A | 1.63% |
| 3-Year Avg Annual Dividend | N/A | $0.11 |
| 3-Year Avg Dividend Yield | N/A | 0.91% |
| 3-Year Total Dividends | N/A | $0.34 |
| Ex-Dividend Date | N/A | Apr 25, 2025 |